Beamion™ LUNG-3 (1479-0032): A Phase III, randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with SOC in patients with early-stage, resectable NSCLC (stage II–IIIB) harboring TKD activating HER2 mutations (NCT07195695)^1,2

*Documented TKD activating HER2 mutations; ^†According to country-specific SOC; IO can include pembrolizumab, atezolizumab, durvalumab or nivolumab; ^‡Time from randomization until recurrence of tumor or death from any cause, whichever is earlier. 
AE, adverse event; DFS, disease-free survival; ECOG PS, Eastern Cooperative Oncology Group performance status; HER2, human epidermal growth factor receptor 2; IO, immunotherapy; NSCLC, non-small cell lung cancer; OS, overall survival; QD, once daily; SOC, standard of care; TKD, tyrosine kinase domain.